Intralesional Bevacizumab for the Treatment of Recurrent Sinonasal Hemangioma

Michael R. Kinzinger, E Bradley Strong, Joan Bernard, Toby Steele

Research output: Contribution to journalArticle

Abstract

INTRODUCTION:: Sinonasal hemangioma is a rare benign tumor of vascular endothelial cells. The pathogenesis is closely linked to abnormalities in the vascular endothelial growth factor signaling pathway. Multiple treatment modalities are available, though wide local excision remains the preferred treatment. Bevacizumab, an anti-vascular endothelial growth factor monoclonal antibody, has known efficacy against hemangiomas, though there are no cases of sinonasal hemangiomas managed with bevacizumab.

METHODS:: Case report.

RESULTS:: The authors review the case of a 67-year-old man with a left-sided nasal hemangioma originating from the nasal septum. He presented with progressive left nasal obstruction and recurrent epistaxis. At the time of his presentation, the lesion had recurred after 1 excision/polypectomy at an outside institution. He then underwent revision surgery via wide local excision and septoplasty. After tumor recurrence following the revision surgery, the hemangioma was noted to recur on 1 year postoperative surveillance nasal endoscopy. In-office intralesional injection of 50 mg bevacizumab was then performed under endoscopic visualization. No improvement in the tumor size was noted at 2 months after injection, with the tumor measuring 1.5 cm. At the 10-month surveillance clinical visit following injection, the tumor had dramatically involuted to 3 mm in greatest dimension. The patient reported complete resolution of his primary symptoms of epistaxis and nasal obstruction.

CONCLUSIONS:: This report demonstrates the first reported successful treatment of a sinonasal hemangioma with intralesional bevacizumab. Intralesional bevacizumab confers an additional option for adjuvant treatment of sinonasal hemangiomas. Further evaluation of intralesional bevacizumab in the treatment of these tumors is warranted.

Original languageEnglish (US)
Pages (from-to)969-973
Number of pages5
JournalThe Annals of otology, rhinology, and laryngology
Volume127
Issue number12
DOIs
StatePublished - Dec 1 2018

Fingerprint

Hemangioma
Neoplasms
Nasal Obstruction
Epistaxis
Reoperation
Nose
Vascular Endothelial Growth Factor A
Therapeutics
Intralesional Injections
Nasal Septum
Injections
Bevacizumab
Endoscopy
Endothelial Cells
Monoclonal Antibodies
Recurrence

Keywords

  • avastin
  • bevacizumab
  • chemotherapy
  • endoscopic sinus surgery
  • hemangioma
  • intralesional therapy
  • nasal
  • septum

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Intralesional Bevacizumab for the Treatment of Recurrent Sinonasal Hemangioma. / Kinzinger, Michael R.; Strong, E Bradley; Bernard, Joan; Steele, Toby.

In: The Annals of otology, rhinology, and laryngology, Vol. 127, No. 12, 01.12.2018, p. 969-973.

Research output: Contribution to journalArticle

@article{c084e8d25c044794bf133497f9f0b574,
title = "Intralesional Bevacizumab for the Treatment of Recurrent Sinonasal Hemangioma",
abstract = "INTRODUCTION:: Sinonasal hemangioma is a rare benign tumor of vascular endothelial cells. The pathogenesis is closely linked to abnormalities in the vascular endothelial growth factor signaling pathway. Multiple treatment modalities are available, though wide local excision remains the preferred treatment. Bevacizumab, an anti-vascular endothelial growth factor monoclonal antibody, has known efficacy against hemangiomas, though there are no cases of sinonasal hemangiomas managed with bevacizumab.METHODS:: Case report.RESULTS:: The authors review the case of a 67-year-old man with a left-sided nasal hemangioma originating from the nasal septum. He presented with progressive left nasal obstruction and recurrent epistaxis. At the time of his presentation, the lesion had recurred after 1 excision/polypectomy at an outside institution. He then underwent revision surgery via wide local excision and septoplasty. After tumor recurrence following the revision surgery, the hemangioma was noted to recur on 1 year postoperative surveillance nasal endoscopy. In-office intralesional injection of 50 mg bevacizumab was then performed under endoscopic visualization. No improvement in the tumor size was noted at 2 months after injection, with the tumor measuring 1.5 cm. At the 10-month surveillance clinical visit following injection, the tumor had dramatically involuted to 3 mm in greatest dimension. The patient reported complete resolution of his primary symptoms of epistaxis and nasal obstruction.CONCLUSIONS:: This report demonstrates the first reported successful treatment of a sinonasal hemangioma with intralesional bevacizumab. Intralesional bevacizumab confers an additional option for adjuvant treatment of sinonasal hemangiomas. Further evaluation of intralesional bevacizumab in the treatment of these tumors is warranted.",
keywords = "avastin, bevacizumab, chemotherapy, endoscopic sinus surgery, hemangioma, intralesional therapy, nasal, septum",
author = "Kinzinger, {Michael R.} and Strong, {E Bradley} and Joan Bernard and Toby Steele",
year = "2018",
month = "12",
day = "1",
doi = "10.1177/0003489418802288",
language = "English (US)",
volume = "127",
pages = "969--973",
journal = "Annals of Otology, Rhinology and Laryngology",
issn = "0003-4894",
publisher = "Annals Publishing Company",
number = "12",

}

TY - JOUR

T1 - Intralesional Bevacizumab for the Treatment of Recurrent Sinonasal Hemangioma

AU - Kinzinger, Michael R.

AU - Strong, E Bradley

AU - Bernard, Joan

AU - Steele, Toby

PY - 2018/12/1

Y1 - 2018/12/1

N2 - INTRODUCTION:: Sinonasal hemangioma is a rare benign tumor of vascular endothelial cells. The pathogenesis is closely linked to abnormalities in the vascular endothelial growth factor signaling pathway. Multiple treatment modalities are available, though wide local excision remains the preferred treatment. Bevacizumab, an anti-vascular endothelial growth factor monoclonal antibody, has known efficacy against hemangiomas, though there are no cases of sinonasal hemangiomas managed with bevacizumab.METHODS:: Case report.RESULTS:: The authors review the case of a 67-year-old man with a left-sided nasal hemangioma originating from the nasal septum. He presented with progressive left nasal obstruction and recurrent epistaxis. At the time of his presentation, the lesion had recurred after 1 excision/polypectomy at an outside institution. He then underwent revision surgery via wide local excision and septoplasty. After tumor recurrence following the revision surgery, the hemangioma was noted to recur on 1 year postoperative surveillance nasal endoscopy. In-office intralesional injection of 50 mg bevacizumab was then performed under endoscopic visualization. No improvement in the tumor size was noted at 2 months after injection, with the tumor measuring 1.5 cm. At the 10-month surveillance clinical visit following injection, the tumor had dramatically involuted to 3 mm in greatest dimension. The patient reported complete resolution of his primary symptoms of epistaxis and nasal obstruction.CONCLUSIONS:: This report demonstrates the first reported successful treatment of a sinonasal hemangioma with intralesional bevacizumab. Intralesional bevacizumab confers an additional option for adjuvant treatment of sinonasal hemangiomas. Further evaluation of intralesional bevacizumab in the treatment of these tumors is warranted.

AB - INTRODUCTION:: Sinonasal hemangioma is a rare benign tumor of vascular endothelial cells. The pathogenesis is closely linked to abnormalities in the vascular endothelial growth factor signaling pathway. Multiple treatment modalities are available, though wide local excision remains the preferred treatment. Bevacizumab, an anti-vascular endothelial growth factor monoclonal antibody, has known efficacy against hemangiomas, though there are no cases of sinonasal hemangiomas managed with bevacizumab.METHODS:: Case report.RESULTS:: The authors review the case of a 67-year-old man with a left-sided nasal hemangioma originating from the nasal septum. He presented with progressive left nasal obstruction and recurrent epistaxis. At the time of his presentation, the lesion had recurred after 1 excision/polypectomy at an outside institution. He then underwent revision surgery via wide local excision and septoplasty. After tumor recurrence following the revision surgery, the hemangioma was noted to recur on 1 year postoperative surveillance nasal endoscopy. In-office intralesional injection of 50 mg bevacizumab was then performed under endoscopic visualization. No improvement in the tumor size was noted at 2 months after injection, with the tumor measuring 1.5 cm. At the 10-month surveillance clinical visit following injection, the tumor had dramatically involuted to 3 mm in greatest dimension. The patient reported complete resolution of his primary symptoms of epistaxis and nasal obstruction.CONCLUSIONS:: This report demonstrates the first reported successful treatment of a sinonasal hemangioma with intralesional bevacizumab. Intralesional bevacizumab confers an additional option for adjuvant treatment of sinonasal hemangiomas. Further evaluation of intralesional bevacizumab in the treatment of these tumors is warranted.

KW - avastin

KW - bevacizumab

KW - chemotherapy

KW - endoscopic sinus surgery

KW - hemangioma

KW - intralesional therapy

KW - nasal

KW - septum

UR - http://www.scopus.com/inward/record.url?scp=85055914930&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055914930&partnerID=8YFLogxK

U2 - 10.1177/0003489418802288

DO - 10.1177/0003489418802288

M3 - Article

VL - 127

SP - 969

EP - 973

JO - Annals of Otology, Rhinology and Laryngology

JF - Annals of Otology, Rhinology and Laryngology

SN - 0003-4894

IS - 12

ER -